文献速递前列腺癌

早期挽救性放疗联合雄激素剥夺治疗在前列腺癌生化复发中的长期多中心结果

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
PubMed 文献 · Eur Urol · 2017-12-08

本研究纳入525例根治性前列腺切除术后生化复发、PSA≤2ng/ml时接受挽救性放疗的患者,中位随访104个月,71例发生转移。多因素分析显示ADT对转移的影响随转移风险而异(p=0.01),仅在早期挽救性放疗中具有侵袭性特征(pT3b/4且Grade group≥4,或pT3b/4且早期挽救性放疗时PSA≥0.4ng/ml)的患者中,ADT与转移率降低相关。

要点

  • 早期挽救性放疗时PSA≤2ng/ml的患者中,34%接受了同期ADT。
  • ADT对转移的影响随多因素模型计算的转移风险而异(p=0.01)。
  • 仅侵袭性特征患者(pT3b/4且Grade group≥4,或pT3b/4且PSA≥0.4ng/ml)在早期挽救性放疗中从ADT获益。

核心结论

  • 同期ADT对早期挽救性放疗的获益随疾病特征显著变化,仅更具侵袭性前列腺癌特征的患者在根治性前列腺切除术后生化复发的早期挽救性放疗中从ADT获益。
  • 低PSA水平且病理特征良好的患者可能免于ADT的潜在副作用。

研究设计与样本

  • 多中心系列研究,共525例根治性前列腺切除术后生化复发、PSA≤2ng/ml时接受挽救性放疗的患者。
  • 中位PSA为0.42ng/ml,中位放疗剂量为66Gy。
  • 178例(34%)患者接受了ADT。
  • 中位随访104个月。

主要发现

  • 71例患者发生转移。
  • Grade group≥4与转移相关(HR 1.66;95%CI 1.01-3.30)。
  • pT3b/4与转移相关(HR 2.61;95%CI 1.51-4.52)。
  • 放疗剂量与转移相关(HR 0.82;95%CI 0.76-0.89)。
  • ADT对转移的影响随多因素模型计算的转移风险而异(p=0.01)。

临床怎么用

  • 对于根治性前列腺切除术后生化复发、PSA≤2ng/ml时接受早期挽救性放疗的患者,应根据疾病特征(如pT3b/4、Grade group≥4、早期挽救性放疗时PSA≥0.4ng/ml)评估是否联合ADT。
  • 低PSA水平且病理特征良好的患者可能避免ADT的潜在副作用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hormonal manipulation concomitant to salvage radiotherapy (SRT) given for biochemical recurrence (BCR) after radical prostatectomy (RP) improved outcomes in two randomized trials. However, neither of these studies focused on men treated at low prostate-specific antigen (PSA) levels. OBJECTIVE: To test if the impact of androgen deprivation therapy (ADT) on metastasis in patients undergoing early SRT varies according to prostate cancer (PCa) features. DESIGN, SETTING, AND PARTICIPANTS: A total of 525 patients received SRT at PSA levels ≤2ng/ml. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Multivariable Cox regression analyses assessed factors associated with metastasis. We tested the hypothesis that the impact of ADT varied according to the risk of metastasis. An interaction with groups (concomitant ADT vs no ADT) and the probability of distant metastasis according to a newly developed model was tested. A nonparametric curve explored the relationship between the risk of metastasis and 10-yr metastasis rates according to ADT. RESULTS AND LIMITATIONS: Median PSA and radiotherapy dose were 0.42ng/ml and 66Gy, respectively. Overall, 178 (34%) patients received ADT. At a median follow-up of 104 mo, 71 patients experienced metastasis. Grade group ≥4 (hazard ratio [HR]: 1.66; 95% confidence interval [CI]: 1.01-3.30), pT3b/4 (HR: 2.61; 95% CI: 1.51-4.52), and dose (HR: 0.82; 95% CI: 0.76-0.89) were associated with metastasis. The impact of ADT differed according to the risk of metastasis calculated using a multivariable model (p=0.01). This was confirmed when considering patients treated with early SRT (p=0.046), where ADT was associated with a reduction in the rate of metastasis only in eSRT; patients with more aggressive characteristics (ie, pT3b/4 and grade group ≥4, or pT3b/4 and PSA at eSRT ≥0.4ng/ml). CONCLUSIONS: The beneficial effect of ADT concomitant to eSRT varied significantly according to disease characteristics, such that only men with more aggressive PCa features benefit from ADT in the eSRT setting for BCR after RP. PATIENT SUMMARY: The oncological benefits of concomitant androgen deprivation therapy (ADT) in patients undergoing salvage radiotherapy (SRT) vary according to pathological characteristics. Only patients with more aggressive disease characteristics seemed to benefit from the use of hormonal manipulation at the time of early SRT. Conversely, the potential side effects of ADT could be spared in patients with low prostate-specific antigen levels and favorable pathological features.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gandaglia G, Fossati N, Karnes RJ, et al. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. Eur Urol. 2017. PMID: 29229176. doi:10.1016/j.eururo.2017.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。